Biosimilars in India; Current Status and Future Perspectives

被引：18
|
作者：
Meher, Bikash R. [1 ]
Balan, Sakthi [2 ]
Mohanty, Rashmi R. [3 ]
Jena, Monalisa [1 ]
Das, Smita [4 ,5 ]
机构：
[1] All India Inst Med Sci, Dept Pharmacol, Bhubaneswar, Odisha, India
[2] Srivenkateshwaraa Med Coll Hosp & Res Ctr, Dept Pharmacol, Pondicherry, India
[3] All India Inst Med Sci, Dept Gen Med, Bhubaneswar, Odisha, India
[4] Inst Med Sci, Dept Pharmacol, Bhubaneswar, Odisha, India
[5] Sum Hosp, Bhubaneswar, Odisha, India
来源：
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES | 2019年 / 11卷 / 01期
关键词：
Biosimilars; European Medicines Agency; Food and Drug Administration; similar biologics; BIOLOGICS; INSULIN;
D O I：
10.4103/jpbs.JPBS_167_18
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in early 2000. India is one of the leading manufacturers of similar biologics. India has developed a new guideline in 2012 for the pre- and post-marketing approval of similar biologics.
引用
收藏
页码：12 / 15
页数：4
相关论文
共 50 条
  • [1] Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
    Park, Sang Hyoung
    Park, Jae Cheol
    Lukas, Milan
    Kolar, Martin
    Loftus, Edward V., Jr.
    [J]. INTESTINAL RESEARCH, 2020, 18 (01) : 34 - 44
  • [2] Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction
    Ylenia Ingrasciotta
    Paola M. Cutroneo
    Ilaria Marcianò
    Thijs Giezen
    Fabiola Atzeni
    Gianluca Trifirò
    [J]. Drug Safety, 2018, 41 : 1013 - 1022
  • [3] Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction
    Ingrasciotta, Ylenia
    Cutroneo, Paola M.
    Marciano, Ilaria
    Giezen, Thijs
    Atzeni, Fabiola
    Trifiro, Gianluca
    [J]. DRUG SAFETY, 2018, 41 (11) : 1013 - 1022
  • [4] Biosimilars Pharmaceutical Market in India: Current Status, Challenges and Future Perspective
    Prakash, Ujalayan Gyan
    Shibu, John
    [J]. BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS, 2021, 14 (01): : 47 - 54
  • [5] Biosimilars in oncology: current and future perspectives
    Aapro, Matti
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (02): : 91 - 93
  • [6] Biosimilars: Current perspectives and future implications
    Misra, Monika
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2012, 44 (01) : 12 - 14
  • [7] Biosimilars: current status and future directions
    Roger, Simon D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (07) : 1011 - 1018
  • [8] Perinatal services in India: Current status and future perspectives
    Singh, M
    [J]. NATIONAL MEDICAL JOURNAL OF INDIA, 2003, 16 : 1 - 4
  • [9] Small hydro power in India: Current status and future perspectives
    Mishra, Mukesh Kumar
    Khare, Nilay
    Agrawal, Alka Bani
    [J]. RENEWABLE & SUSTAINABLE ENERGY REVIEWS, 2015, 51 : 101 - 115
  • [10] Current status, issue and future perspectives for biosimilars in Japan from the viewpoint of cost-effectiveness
    Nanbu, Yoshihiro
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 36 - 36
12345